SCHEMBL3363799

SCHEMBL3363799

CN1CCCN(c2cncc(-c3cncc(C=C4SC(=S)NC4=O)c3)n2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 6/20 0.50
PIM2 Q9P1W9 8/20 0.49
CSNK2A2 P19784 1/20 0.49
CSNK2A1 P68400 1/20 0.49
PIM3 Q86V86 2/20 0.44
ADAMTS5 Q9UNA0 1/20 0.41
CISD1 Q9NZ45 2/20 0.39
MAOA P21397 1/20 0.39
MEN1 O00255 2/20 0.38
MAPT P10636 2/20 0.38
KMT2A Q03164 2/20 0.38
NSD2 O96028 1/20 0.38
POLB P06746 1/20 0.38
HSP90AA1 P07900 1/20 0.38
MAPK1 P28482 1/20 0.38
PTGS2 P35354 1/20 0.38
DNM1 Q05193 1/20 0.38
PLA2G1B P04054 1/20 0.38
NOD2 Q9HC29 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3363795 1.00 PIM1 (0.50) PIM1PIM2CSNK2A2CSNK2A1PIM3
SCHEMBL3362852 0.91 PIM2 (0.51) PIM1PIM2CSNK2A2CSNK2A1PIM3
SCHEMBL3362857 0.91 PIM2 (0.51) PIM1PIM2CSNK2A2CSNK2A1PIM3
SCHEMBL3366398 0.90 PIM2 (0.60) PIM1PIM2CSNK2A2CSNK2A1PIM3
SCHEMBL12990158 0.90 PIM2 (0.60) PIM1PIM2CSNK2A2CSNK2A1PIM3
SCHEMBL3366393 0.90 PIM2 (0.60) PIM1PIM2CSNK2A2CSNK2A1PIM3
SCHEMBL3366640 0.84 PIM1 (0.51) PIM1PIM2CSNK2A2CSNK2A1PIM3
SCHEMBL3366644 0.84 PIM1 (0.51) PIM1PIM2CSNK2A2CSNK2A1PIM3
SCHEMBL3362258 0.84 PIM1 (0.47) PIM1PIM2CSNK2A2CSNK2A1PIM3
SCHEMBL3362165 0.84 PIM1 (0.49) PIM1PIM2CSNK2A2CSNK2A1PIM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010148351-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM2, PIM1, CDK2 PIM1 2/4885PIM2 1/4885CSNK2A2 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.